WO2005110464A3 - Irx5 inhibition as treatment for hyperproliferative disorders - Google Patents

Irx5 inhibition as treatment for hyperproliferative disorders Download PDF

Info

Publication number
WO2005110464A3
WO2005110464A3 PCT/US2005/016830 US2005016830W WO2005110464A3 WO 2005110464 A3 WO2005110464 A3 WO 2005110464A3 US 2005016830 W US2005016830 W US 2005016830W WO 2005110464 A3 WO2005110464 A3 WO 2005110464A3
Authority
WO
WIPO (PCT)
Prior art keywords
irx5
hyperproliferative disorders
inhibition
treatment
irx6
Prior art date
Application number
PCT/US2005/016830
Other languages
French (fr)
Other versions
WO2005110464A2 (en
Inventor
Tomasz M Beer
Anne Myrthue
Original Assignee
Univ Oregon Health & Science
Tomasz M Beer
Anne Myrthue
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Tomasz M Beer, Anne Myrthue filed Critical Univ Oregon Health & Science
Publication of WO2005110464A2 publication Critical patent/WO2005110464A2/en
Publication of WO2005110464A3 publication Critical patent/WO2005110464A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

This disclosure relates to inhibition of the Iroquois family of nucleic acids and/or proteins, such as IRX1, IRX2, IRX3, IRX4, IRX5, or IRX6 in the treatment of hyperproliferative disorders. In particular, pharmaceuticals and other compositions including an IRX5 inhibitor (such as an IRX5-specific siRNA or shRNA and methods of using IRX5 inhibitors (alone or in combination therapy)to treat hyperproliferative disorders (such as neoplasia) are described.
PCT/US2005/016830 2004-05-14 2005-05-13 Irx5 inhibition as treatment for hyperproliferative disorders WO2005110464A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57104304P 2004-05-14 2004-05-14
US60/571,043 2004-05-14

Publications (2)

Publication Number Publication Date
WO2005110464A2 WO2005110464A2 (en) 2005-11-24
WO2005110464A3 true WO2005110464A3 (en) 2006-12-07

Family

ID=35394673

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/016830 WO2005110464A2 (en) 2004-05-14 2005-05-13 Irx5 inhibition as treatment for hyperproliferative disorders

Country Status (1)

Country Link
WO (1) WO2005110464A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646997B2 (en) * 2007-10-03 2014-12-24 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Novel siRNA structure
EP2985348B1 (en) * 2009-07-24 2020-12-30 CuRNA, Inc. Treatment of sirtuin 6 (sirt6) related diseases by inhibition of natural antisense transcript to sirt6
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
EP3237642A4 (en) * 2014-12-24 2018-09-19 Massachusetts Institute of Technology Compositions and methods for manipulation of adipocyte energy consumption regulatory pathway
CN114032339B (en) * 2021-12-22 2023-09-01 湖南工程学院 Hyperbranched hybridization chain reaction signal amplification system for detecting nasopharyngeal carcinoma, kit and detection method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063975A2 (en) * 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US20030119795A1 (en) * 1998-03-27 2003-06-26 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119795A1 (en) * 1998-03-27 2003-06-26 Oregon Health & Science University Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders
WO1999063975A2 (en) * 1998-06-10 1999-12-16 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH A method for stimulating the immune system
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADAMS A.: "RNA therapeutics center clinical trials", THE SCIENTIST, 2005, XP002992230 *
CAPLEN N.J.: "RNAi as a gene therapy approach", GENE THERAPY, 2003, XP008055014 *
GREEN ET AL.: "Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human diseases", J AM COLL SURG, vol. 191, 2000, pages 93 - 105, XP002948604 *
HAMMOND S.M. ET AL.: "Post-transcriptional gene silencing by double-stranded RNA", NATURE REVIEWS, vol. 2, February 2001 (2001-02-01), pages 110 - 119, XP003004939 *

Also Published As

Publication number Publication date
WO2005110464A2 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
WO2010074588A8 (en) Pharmaceutical compounds
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
WO2005110994A8 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
WO2009114725A3 (en) Mobilization op hematopoietic stem cells using cdc42 inhibitors
WO2007026251A8 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2008033562A3 (en) Kinase inhibitor compounds
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2005117846A3 (en) Ice inhibitors for the treatment of autoinflammatory diseases
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2004108139A3 (en) Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
TW200630090A (en) Triazoles useful as inhibitors of protein kinases
MX2010006203A (en) Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases.
TW200514776A (en) Aminotriazole compounds useful as inhibitors of protein kinases
EP2426203A3 (en) Agents useful in treating facioscapulohumeral muscular dystrophy
MX2009006535A (en) Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors.
WO2004071448A3 (en) Substituted azole derivatives as inhibitors of protein tyrosine phosphatases
WO2006023866A3 (en) Thiazolo-naphthyl acids as inhibitors of plasminogen activator inhibitor-1
WO2008039829A3 (en) Diphenylheterocycle cholesterol absorption inhibitors
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2004017948A3 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2006075095A3 (en) Use of purine derivatives as hsp90 protein inhibitors and for treatment of cancer
WO2009062576A3 (en) Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
WO2005110464A3 (en) Irx5 inhibition as treatment for hyperproliferative disorders
WO2010011700A3 (en) Treatment of cancers characterized by chromosomal rearrangement of the nut gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase